(Q33756929)

English

Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

29 July 2017

0 references

Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis (English)

1 reference

Europe PubMed Central

29 July 2017

0 references

Crohn's disease

0 references

5

object named as

Bruce E Sands

1 reference

Europe PubMed Central

29 July 2017

author name string

Corey A Siegel

1

1 reference

Europe PubMed Central

29 July 2017

Sadie M Marden

2

1 reference

Europe PubMed Central

29 July 2017

Sarah M Persing

3

1 reference

Europe PubMed Central

29 July 2017

Robin J Larson

4

1 reference

Europe PubMed Central

29 July 2017

language of work or name

0 references

publication date

24 January 2009

1 reference

Europe PubMed Central

29 July 2017

Clinical Gastroenterology and Hepatology

1 reference

Europe PubMed Central

29 July 2017

7

1 reference

Europe PubMed Central

29 July 2017

8

1 reference

Europe PubMed Central

29 July 2017

874-881

1 reference

Europe PubMed Central

29 July 2017

Are adult patients more tolerant of treatment risks than parents of juvenile patients?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2846413

21 June 2018

Diagnostic ionizing radiation exposure in a population-based cohort of patients with inflammatory bowel disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2846413

21 June 2018

Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2846413

21 June 2018

Computed Tomography — An Increasing Source of Radiation Exposure

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2846413

21 June 2018

Humoral and cellular monitoring to predict the development of infection in Crohn's disease patients beginning treatment with infliximab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2846413

21 June 2018

Crohn's disease patients' risk-benefit preferences: serious adverse event risks versus treatment efficacy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2846413

21 June 2018

Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2846413

21 June 2018

Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2846413

21 June 2018

Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2846413

21 June 2018

Safety aspects of infliximab in inflammatory bowel disease patients. A retrospective cohort study in 100 patients of a German University Hospital

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2846413

21 June 2018

Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2846413

21 June 2018

Infliximab maintenance therapy for fistulizing Crohn's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2846413

21 June 2018

The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2846413

21 June 2018

Immunomodulators and "on demand" therapy with infliximab in Crohn's disease: clinical experience with 400 infusions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2846413

21 June 2018

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2846413

21 June 2018

Risk of lymphoma in inflammatory bowel disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2846413

21 June 2018

Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2846413

21 June 2018

Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2846413

21 June 2018

Crohn's disease: factors associated with exposure to high levels of diagnostic radiation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2846413

30 October 2018

Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2846413

30 October 2018

Combining infliximab with methotrexate for the induction and maintenance of remission in refractory Crohn's disease: a controlled pilot study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2846413

30 October 2018

[Efficacy and safety of treatment with infliximab in Crohn's disease-the experience of single center in Korea].

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2846413

30 October 2018

Infliximab in the surgical management of complex fistulating anal Crohn's disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2846413

30 October 2018

Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2846413

30 October 2018

Retreatment and maintenance therapy with infliximab in fistulizing Crohn's disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2846413

30 October 2018

Perianal fistulae following infliximab treatment: clinical and endosonographic outcome.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2846413

30 October 2018

Combining infliximab and methotrexate in fistulizing Crohn's disease resistant or intolerant to azathioprine.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2846413

30 October 2018

Efficacy and safety of repeated infliximab infusions for Crohn's disease: 1-year clinical experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2846413

30 October 2018

Inflammatory bowel disease is not associated with an increased risk of lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19558997

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adalimumab maintenance therapy for Crohn's disease with intolerance or lost response to infliximab: an open-label study

1 reference

https://pubmed.ncbi.nlm.nih.gov/19558997

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/19558997

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/19558997

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States

1 reference

https://pubmed.ncbi.nlm.nih.gov/19558997

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cancer risk in patients with inflammatory bowel disease: a population-based study

1 reference

https://pubmed.ncbi.nlm.nih.gov/19558997

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/19558997

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of time trends in Hodgkin and non-Hodgkin lymphoma incidence (1973-97) in East Asia, Europe and USA, from cancer incidence in five continents Vol. IV-VIII

1 reference

https://pubmed.ncbi.nlm.nih.gov/19558997

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/J.CGH.2009.01.004

1 reference

Europe PubMed Central

29 July 2017

1 reference

Europe PubMed Central

29 July 2017

1 reference

Europe PubMed Central

29 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33756929&oldid=1569394841"